AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36477706
Drug: Sugammadex 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2.0 mg/kg
Trial: 33845881
Drug: N-Acetylcysteine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (300 mg/kg equivalent to 20 gr as a slow single intravenous injection on the first day of hospitalization)
Trial: 33845881
Drug: Placebo (Sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Sterile water for injection, identical in appearance to N-Acetylcysteine)
Trial: 36075260
Drug: Rezvilutamide plus
RxNorm normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezvilutamide plus ADT (240 mg daily)
Trial: 36075260
Drug: Bicalutamide plus
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide plus ADT (50 mg daily)
Trial: 35689084
Drug: Low-Dose atDCS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose atDCS
Trial: 35689084
Drug: High-Dose atDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose atDCS
Trial: 35689084
Drug: Combined atDCS
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined atDCS group (Low-Dose + High-Dose)
Trial: 36001383
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with standard platinum-based chemotherapy
Trial: 39096924
Drug: Standard platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard platinum-based chemotherapy
Trial: 32740081
Drug: 1 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Hz translumbosacral neuromodulation therapy (TNT)
Trial: 32740081
Drug: 5 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Hz translumbosacral neuromodulation therapy (TNT)
Trial: 32740081
Drug: 15 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 Hz translumbosacral neuromodulation therapy (TNT)
Trial: 32740081
Drug: 1 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Hz and 5 Hz translumbosacral neuromodulation therapy (TNT)
Trial: 32118463
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text messages containing accurate drinking norms (n = 61)
Trial: 35972453
Drug: Progesterone vaginal
RxNorm normalized name: progesterone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone vaginal tablets, 100 mg twice daily, starting from the day of embryo transfer
Trial: 33645069
Drug: Icaritin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icaritin (5 μmol·L(‐1))
Trial: 33645069
Drug: Icaritin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icaritin (10 μmol·L(‐1))
Trial: 33645069
Drug: Icaritin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icaritin (20 μmol·L(‐1))
Trial: 34304346
Drug: Targeted antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted antibiotic prophylaxis based on rectal swab results
Trial: 33727034
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care (manual assessment three times daily using a portable manometer)
Trial: 35503024
Drug: Internet-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based Cognitive Behavioral Therapy (ICBT) for 7 weeks
Trial: 32009486
Drug: 5-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-g oral collagen hydrolysate (CH) daily for 4 weeks
Trial: 32623370
Drug: Drainage, irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drainage, irrigation and fibrinolytic therapy (DRIFT)
Trial: 37149930
Drug: MSC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC treatment
Trial: 36398114
Drug: Low-Intensity Vibration
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Vibration (LIV) - 0.4 g at 30 Hz for 10 min/day
Trial: 32840458
Drug: Kinesio Taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio Taping following Manual Therapy (KTMT)
Trial: 34058071
Drug: GDC-0334 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0334 (25 mg starting dose)
Trial: 33475753
Drug: No OSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No OSA management or treatment
Trial: 36380290
Drug: Intervention for
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention for Appropriate Care and Treatment (InterACT) trial
Trial: 35806937
Drug: Oral antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiplatelet treatment
Trial: 32332636
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) with basic western medicine (BWC)
Trial: 32332636
Drug: Basic western
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic western medicine (BWC)
Trial: 32332636
Drug: Sham electroacupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham electroacupuncture (sham EA) with basic western medicine (BWC)
Trial: 34392795
Drug: Constraint‐induced movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐induced movement therapy (CIMT) and neurostimulation paired with intensive, goal‐directed therapy
Trial: 32005160
Drug: 20 mL ropivacaine
RxNorm normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL ropivacaine (7.5 mg/mL)
Trial: 32005160
Drug: 20 mL saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL saline (placebo)
Trial: 32959591
Drug: Electroacupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture combined with Yuyin pill
Trial: 32959591
Drug: Yuyin pill
RxNorm normalized name: Yujin (Curcuma Longa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yuyin pill alone
Trial: 33423966
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with capecitabine for 6 months
Trial: 33423966
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiochemotherapy
Trial: 34730887
Drug: SHP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP block with bupivacaine injection
Trial: 34730887
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with saline injection
Trial: 34964679
Drug: Mobilization +
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilization + Physical Therapy
Trial: 34881911
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy for PTSD (DBT-PTSD)
Trial: 34928359
Drug: Cisplatin-based CCRT
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based CCRT (100 mg/m2 every 3 weeks for 3 cycles)
Trial: 34928359
Drug: Nedaplatin-based CCRT
RxNorm normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedaplatin-based CCRT (100 mg/m2 every 3 weeks for 3 cycles)
Trial: 32618037
Drug: T. chebula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T. chebula 250 mg
Trial: 32618037
Drug: T. chebula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T. chebula 500 mg
Trial: 32857471
Drug: SPL 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPL 25 mg/day plus topical benzoyl peroxide (BP) 2.5%
Trial: 32857471
Drug: SPL 50
RxNorm normalized name: AVOBENZONE 3 g in 100 g / HOMOSALATE 10 g in 100 g / OCTISALATE 5 g in 100 g / OCTOCRYLENE 5 g in 100 g / OCTINOXATE 7.5 g in 100 g TOPICAL SPRAY [Bull Frog Mosquito Coast SPL 50 Pump]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPL 50 mg/day plus topical benzoyl peroxide (BP) 2.5%
Trial: 32857471
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus topical benzoyl peroxide (BP) 2.5%
Trial: 33749220
Drug: 1% sodium
RxNorm normalized name: Dextrose 5% and 0.11% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% sodium hexametaphosphate (SHMP) added to a 3% hydrogen peroxide bleaching gel applied for 6 hours per night for 2 weeks
Trial: 33749220
Drug: 3% hydrogen
RxNorm normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [3% Hydrogen Peroxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% hydrogen peroxide bleaching gel (control group)
Trial: 36050204
Drug: Spinal Cord
RxNorm normalized name: BOS TAURUS SPINAL CORD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal Cord Stimulation (SCS) therapy (40-Hz tonic SCS)
Trial: 32406998
Drug: SYNERGY bioabsorbable
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNERGY bioabsorbable polymer drug-eluting stent (BP-DES)
Trial: 32414330
Drug: Durable polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durable polymer drug-eluting stent (DP-DES)
Trial: 32163564
Drug: OCP (ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCP (ethinylestradiol 30 μg/desogestrel 150 μg or ethinylestradiol 30 μg/drospirenone 3 mg) for 12-30 days with a 5-day washout period
Trial: 34658781
Drug: Neuravena® (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuravena® (800 mg)
Trial: 32917359
Drug: Indacaterol/glycopyrronium 110/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium 110/50 μg via Breezhaler® (IND/GLY)
Trial: 32917359
Drug: Salbutamol/ipratropium 2.5/0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol/ipratropium 2.5/0.5 mg via air driven nebulization (SAL/IPR)
Trial: 36062127
Drug: Juan Bi
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juan Bi Tang (JBT) - 3 g thrice daily for 4 weeks
Trial: 36062127
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for 4 weeks
Trial: 35155599
Drug: Tolvaptan add-on
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan add-on therapy
Trial: 36210496
Drug: Balance exercises
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance exercises with mirror therapy
Trial: 36210496
Drug: Balance exercises
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance exercises without mirror therapy (control)
Trial: 37167798
Drug: NPA-O2 (nasopharyngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPA-O2 (nasopharyngeal apnoeic oxygenation at 18 l/min)
Trial: 32770667
Drug: Generic (test)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic (test) formulation of 10‐mg alfuzosin extended‐release tablets
Trial: 32770667
Drug: Branded (reference)
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded (reference) formulation of 10‐mg alfuzosin extended‐release tablets
Trial: 33273475
Drug: Anti-hepatitis B
RxNorm normalized name: Anti-Hepatitis Be virus IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hepatitis B core antibody (anti-HBc) testing
Trial: 33273475
Drug: Antibodies against
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies against hepatitis C virus (anti-HCV) testing
Trial: 32965623
Drug: MEL (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEL (3 mg) before exercise
Trial: 32560181
Drug: Phe-10 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phe-10 g
Trial: 32560181
Drug: Phe-5 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phe-5 g
Trial: 36053605
Drug: Haemoglobin <50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoglobin <50 g/L
Trial: 32800385
Drug: High-protein group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein group (target energy 20 kcal/kg/day, protein 1.8 g/kg/day)
Trial: 32800385
Drug: Medium-protein group
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-protein group (target energy 20 kcal/kg/day, protein 0.9 g/kg/day)
Trial: 34702773
Drug: Ceritinib administered
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib administered for 10 days prior to tumor resection
Trial: 35898448
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (intramuscular testosterone cypionate 200 mg every 2 weeks for 18 months)
Trial: 616761389
Drug: Daily activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily activity feedback (steps and active minutes) via an online program
Trial: 32212002
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) treatment
Trial: 34185225
Drug: Change scores
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change scores and effect sizes across treatment response categories
Trial: 34550930
Drug: Subfascial breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subfascial breast augmentation
Trial: 35634285
Drug: SARS-CoV-2-mRNA vaccination
RxNorm normalized name: SARS-CoV-2 mRNA vaccine
DrugBank: SARS-CoV-2 mRNA vaccine (DB15855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2-mRNA vaccination in IBD patients treated with TNF-α inhibitors
Trial: 32592973
Drug: 80-kVp protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-kVp protocol with 60 ml CM and ASIR-V
Trial: 32592973
Drug: 80-kVp protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-kVp protocol with 45 ml CM and ASIR-V
Trial: 32592973
Drug: 120-kVp protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120-kVp protocol with 60 ml CM and filtered back projection
Trial: 36031855
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy delivered using an MP3 player and headphones
Trial: 33539062
Drug: Efinaconazole 10%
RxNorm normalized name: EFINACONAZOLE 10% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efinaconazole 10% topical solution applied once daily for 18-24 months
Trial: 35245284
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ITCs and ITJCs
Trial: 32122397
Drug: Prophylactic swallowing
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic swallowing exercises (PSE) with face-to-face therapy by a speech and language pathologist
Trial: 33729038
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) plus 36 sessions of group exercise
Trial: 33711991
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate sodium (PPS) 2 mg/kg, subcutaneous, twice weekly for 6 weeks
Trial: 34508594
Drug: Sarilumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab monotherapy (200 mg every 2 weeks)
Trial: 33735463
Drug: Rocking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocking therapy for a minimum of 20 minutes daily
Trial: 33735463
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with same type of chair but without rocking therapy
Trial: 39560745
Drug: Carbohydrate counting
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate counting (CC)
Trial: 32215726
Drug: Potato-based products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato-based products (1.6 g kg-1)
Trial: 32215726
Drug: Sport supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sport supplements (1.6 g kg-1)
Trial: 38806190
Drug: upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 15 mg once daily
Trial: 35332058
Drug: upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 15 mg once daily (switched from placebo)
Trial: 35341943
Drug: Ayurcov (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurcov (three doses on Day 1 as an adjuvant to standard of care)
Trial: 32349059
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg loading dose intravenous infusion 30 minutes before surgery and again 3 hours later (Group C)
Trial: 32349059
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg loading dose intravenous infusion 30 minutes before surgery (Group B)
Trial: 32349059
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline solution without TXA (Group A)
Trial: 32078815
Drug: All vaccine
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All vaccine regimens
Trial: 34253077
Drug: Amplification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amplification of Positivity Therapy (AMP) for alcohol use (AMP‐A) delivered in 11 individual sessions
Trial: 33554268
Drug: Gentamicin ointment
RxNorm normalized name: gentamicin Ophthalmic Ointment
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin ointment
Trial: 32540584
Drug: High-volume corticosteroid
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume corticosteroid injection (1 mL triamcinolone acetonide/40 mg, 9 mL anaesthetic agents)
Trial: 32540584
Drug: Low-volume corticosteroid
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume corticosteroid injection (1 mL triamcinolone acetonide/40 mg)
Trial: 35860380
Drug: Oral probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotics (control group).
Trial: 32698457
Drug: Pistachio group
RxNorm normalized name: Pistachio
DrugBank: Pistachio (DB10559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistachio group (1.5 oz/day or 42 g/day)
Trial: 32597580
Drug: Phenazopyridine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenazopyridine (200 mg, 2 tablets of 100 mg p.o., once)
Trial: 32597580
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same administration scheme as phenazopyridine)
Trial: 32329767
Drug: Intranasal Naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Naloxone
Trial: 32329767
Drug: Intramuscular Naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Naloxone
Trial: 33526730
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg/day (group 1, n=30)
Trial: 35413714
Drug: A. annua
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A. annua extracts sublingual immunotherapy (SLIT) with pharmacotherapy
Trial: 32059728
Drug: Combined Aerobic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Aerobic and Resistance Exercise (CARE) program during chemotherapy
Trial: 32206987
Drug: Xuezhitong (XZT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhitong (XZT) 2700 mg daily
Trial: 32206987
Drug: Xuezhikang (XZK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (XZK) 1200 mg daily
Trial: 36965232
Drug: Brief Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Behavioral Therapy (BBT)
Trial: 33302685
Drug: TNF-α antagonist
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNF-α antagonist etanercept 25 mg subcutaneous injection two times a week for two weeks
Trial: 35476651
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (no nasal high-flow therapy or supplemental oxygen)
Trial: 34225270
Drug: Cyclic steroid‐cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic steroid‐cyclophosphamide regimen (modified Ponticelli protocol)
Trial: 34225270
Drug: Rituximab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1 g × 2)
Trial: 37855022
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (both doses)